CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials

Authors:

Abstract
No abstract available
Funding Information
  • Children's Hospital of Philadelphia
  • University of Pennsylvania
  • National Institutes of Health (5K12CA076931–22, 5P01CA214278–04)
  • Novartis Pharmaceuticals Corporation
  • Pfizer

This publication has 27 references indexed in Scilit: